At the end of one year, likelihood of being weaned off treatment was higher for eyes treated with aflibercept versus bevacizumab
Your search for bevacizumab returned 79 results
Outcomes at 2 years comparable among patients with diabetic macular edema receiving aflibercept monotherapy, bevacizumab first
Pembrolizumab plus chemotherapy with or without bevacizumab could be a new standard of care for first-line therapy in metastatic cervical cancer.
There was no improvement in overall survival with bevacizumab.
Phase 1 study suggests that intravitreous injection of 0.004mg may be lowest effective dose.
And, triplet and doublet drug regimens delay decline in quality of life in BRAF V600E metastatic CRC.
Addition of bevacizumab to carboplatin/pemetrexed beneficial in advanced non-small cell lung cancer
The researchers found that the hazard ratio for progression-free survival was 0.74 and 0.83 for atezolizimab plus bevacizumab versus sunitinib in PD-L1+ patients and intention-to-treat patients, respectively.
After completion of the initial bevacizumab treatment cycle, there was a significant reduction in epistaxis severity scores and RBC transfusion requirements.
However, locally assessed progression-free survival was 2.7 months longer in the combination group than in the monotherapy group.